Purchase Order 75D30123P15957
- Not listed
- This federal contract award is for the procurement of lab instrument software from Oxford Nanopore Technologies Inc., a foreign-owned, for-profit biotechnology company. The $12,500 firm-fixed-price purchase order was issued by the Centers for Disease Control and Prevention (CDC) Pittsburgh office, a civilian agency, with a completion date of August 31, 2024. Oxford Nanopore Technologies is a provider of next-generation genomic sequencing equipment, consumables, and associated services to various...
- This federal contract award to Oxford Nanopore Technologies Inc., a foreign-owned for-profit biotechnology company, is for the provision of sequencing technology and associated services to support research initiatives. The $20,210 firm fixed price purchase order, awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh, does not have a set-aside designation. Oxford Nanopore Technologies holds additional federal contract vehicles, including a $300,000 blanket purchase...
- This federal contract award, valued at $12,500.00, was made by the Centers for Disease Control and Prevention (CDC) Pittsburgh to Oxford Nanopore Technologies Inc., a foreign-owned, for-profit biotechnology company. The contract is for a GridION software license and device warranty. Oxford Nanopore Technologies specializes in nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins, and has secured numerous federal contracts to supply next-generation...
- This is a federal purchase order award to Oxford Nanopore Technologies Inc., a foreign-owned, for-profit biotechnology company, for the delivery of ONT MinION sequencing kits. The $21,577 firm-fixed-price contract was awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh office, a civilian agency, with a period of performance ending on September 29, 2024. No set-aside was used for this award. Oxford Nanopore Technologies is a prime contractor for this purchase order and...
- This is a $48,400.00 firm-fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Oxford Nanopore Technologies Inc., a foreign-owned for-profit biotechnology company. The contract is for the delivery of laboratory supplies, with no set-aside designation. Oxford Nanopore Technologies Inc. has secured numerous prime federal contracts and subcontracts with agencies like the NIH, USDA, and DOD, primarily for the provision of next-generation genomic sequencing...
- This is a federal contract award to Oxford Nanopore Technologies Inc., a foreign-owned, for-profit biotechnology company, by the Centers for Disease Control and Prevention (CDC) Pittsburgh, a civilian federal agency. The contract is for the delivery of laboratory equipment, specifically next-generation genomic sequencing devices, consumables, and associated services. The contract has no set-aside designation and is a firm fixed-price purchase order with a ceiling value of $68,067.00. The award...
- This is a $95,755 firm-fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Oxford Nanopore Technologies Inc., a foreign-owned, for-profit biotechnology company, for the acquisition of GridION MK1 CAPEX equipment. The award has no set-aside designation. Oxford Nanopore Technologies Inc. has received multiple prime federal contract awards from agencies such as the NIH, USDA, and DOD to provide next-generation genomic sequencing platforms, consumables,...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $140,950 firm fixed price purchase order to Oxford Nanopore Technologies Inc., a foreign-owned for-profit organization, for the GRIDION MK1 CAPEX. The contract, which does not have a set-aside designation, is for the delivery of Oxford Nanopore's nanopore sequencing devices, flow cells, reagents, kits, software, and related services and support. The contract will be performed in Lexington,...
- This firm fixed-price purchase order, valued at $16,199.00, was awarded by the Centers for Disease Control and Prevention (CDC) to Oxford Nanopore Technologies Inc., a foreign-owned for-profit biotechnology company. The contract provides for the delivery of Oxford Nanopore's VOLTRAX V2 CAPEX equipment, which is part of their nanopore-based electronic systems used for real-time analysis of genetic materials and other biological molecules. The contract has no set-aside designation. Oxford Nanopore...
- This firm fixed price purchase order was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) to Oxford Nanopore Technologies Inc., a subsidiary of Oxford Nanopore Technologies PLC, to provide lab equipment. The contract, which has a potential value of $106,097.00, does not have a set-aside designation and was awarded on August 27, 2021, with a completion date of September 30, 2021. Based on Oxford Nanopore Technologies' prior federal contract...
Oxford Nanopore Technologies Inc., a foreign-owned, for-profit biotechnology company, was awarded a $9,350 firm fixed-price purchase order (Contract ID 75D30123P15957) by the Centers for Disease Control and Prevention (CDC) Pittsburgh office, a civilian agency, for equipment software licenses and warranties. The contract has an ultimate completion date of April 30, 2023 and does not utilize a set-aside. This award is part of Oxford Nanopore's broader portfolio of federal contracts, which include Blanket Purchase Agreements (BPAs) with the Defense Health Agency ($325,000), USDA Agricultural Research Service ($300,000), and Air Force Life Cycle Management Center ($250,000) to provide sequencing technologies and associated services to support various government research initiatives across agencies such as the National Institutes of Health, USDA, and Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Other Administrative Action | $0 | 8/29/23 | |
| P00001 | Other Administrative Action | $0 | 3/21/23 | |
| Not listed | Not listed | $9.4k | 1/27/23 |